6 October 2020 - - US-based precision therapeutics company Q-State Biosciences has appointed Paul Medeiros as president and chief executive officer of the company, the company said.

With nearly 25 years of global executive pharmaceutical experience, Medeiros is a proven business leader with an extensive track record of success in biopharma strategy, operations, R and D portfolio and corporate development.

He will lead the company's efforts to bring its first therapeutic candidates into the clinic.

Medeiros joins Q-State from Imbrium Therapeutics, where he served as president and founding executive, directing the company's business operations and R and D portfolio in the areas of pain and CNS therapeutics.

He concurrently served as president of the associated investment / accelerator firm Greenfield BioVentures. In addition to these roles, Medeiros has fulfilled multiple corporate leadership positions within other biopharmaceutical companies including Mundipharma International in Cambridge UK, AVI BioPharma (now Sarepta Therapeutics), and Schering-Plough Pharmaceuticals.

He began his pharma career as an MBA leadership trainee at Merck and company. Medeiros has served on the board of directors of Praxis Precision Medicines, Kolltan Pharmaceuticals and EDO Pharmaceuticals GMBH. He received his AB with Honors from Brown University and his MBA from Columbia Business School.

Q-State Biosciences is a precision therapeutics company based in Cambridge, MA that develops transformative treatments for diseases associated with electrically excitable cells.

Q-State applies proprietary human cellular models, unique optogenetic measurement tools and deep, machine learning analytics to discover and optimise new targeted medicines for diseases with high unmet need.